La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Zedge a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Zedge..

Zedge (AMEX:ZDGE) Azioni, Catena delle Opzioni

Zedge

Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.

AdobeStockholm,,Sweden,-,July,26,,2021:,A,Wall,Sign,For

Pre-Market Outlook

ADBE

FGEN

ZDGE

Un colosso tech crolla nonostante utili record, mentre un&#39;azione del lusso vola del 20%. I movimenti che agitano i mercati.

Adobe, RH e altre 3 azioni da tenere d&#39;occhio in questo venerdì

Zedge Inc

Keybanc analyst Eric Heath downgrades Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) from Overweight to Sector Weight.

News

Downgrades

Analyst Ratings

PANW

Keybanc Downgrades Palo Alto Networks to Sector Weight

NAMM

Namib Minerals Issues Corporate Update Following Nasdaq Listing And Closing Bell Ceremony, Accelerates Redwing Dewatering And Mazowe Infrastructure Upgrades

Keybanc analyst Jackson Ader upgrades Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) from Sector Weight to Overweight and announces $630 price target.

Upgrades

Price Target

MSFT

Keybanc Upgrades Microsoft to Overweight, Announces $630 Price Target

<ul>
<li>As part of the NXP800 Phase 1b study, 17 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer were treated with NXP800 at the target dose of 75 mg/day, administered intermittently or daily, with data available for 13 patients. Overall, treatment resulted in 2 patients achieving partial response (unconfirmed) and 3 achieving stable disease. Thrombocytopenia, a key toxicity identified early in the study, was successfully managed following the switch to intermittent dosing. The company will not pursue further development of NXP800 in ovarian cancer but, in the coming months, will evaluate the feasibility of development opportunities for NXP800 in other cancer types, such as endometrial and prostate cancers, in which the patients' performance status and other characteristics may allow treatment with NXP800 to be more impactful.</li>
<li>With the recent successful completion of the NXP900 DDI study, which supports the potential combination of NXP900 with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer (NSCLC), and now the successful completion of the Phase 1a dose-escalation study, the Company is poised for the start of the Phase 1b study of NXP900, expected in the coming weeks. The Phase 1a dose escalation study evaluated the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of NXP900 in patients with advanced solid tumors (all comers). In this study, a dose range of 20 to 300 mg/day was evaluated and the dose limiting toxicity dose level was not reached. As presented by the study investigators at the 2025 American Association for Cancer Research (AACR) conference, the most common treatment emergent adverse events were mainly gastrointestinal-related and mild to moderate in intensity; systemic exposure to NXP900 increased with increased doses and a robust pharmacodynamic response of approximately 90% inhibition of SRC kinase phosphorylation was elicited at doses of 150 mg/day and higher, suggesting a potentially wide therapeutic window. The final data from the study is expected to be presented at a future medical/scientific conference.</li>
<li>Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases; thrombocytopenia successfully managed with intermittent dosing schedule; observed clinical activity warrants exploration of potential development opportunities in other cancer types</li>
<li>NXP900 successfully completed a clinical drug-drug interaction (DDI) study in healthy volunteers and the Phase 1a dose escalation study; initiation of the NXP900 Phase 1b program to evaluate the safety and efficacy of NXP900 as a single agent and in combination with other anti-cancer agents expected in the coming weeks</li>
</ul>

Biotech

Health Care

General

NVCT

Nuvectis Pharma Shared Final Clinical Data Update From The Phase 1b Study Of NXP800 In Recurrent, Platinum Resistant, ARID1a-mutated Ovarian Cancer And Reported On The Progress Towards The Initiation Of The Phase 1b Program For NXP900

Peabody Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.01) by 2200 percent. This is a 116.2 percent decrease over earnings of $1.42 per share from the same period last year. The company reported quarterly sales of $890.100 million which missed the analyst consensus estimate of $944.200 million by 5.73 percent. This is a 14.58 percent decrease over sales of $1.042 billion the same period last year.

Earnings

Earnings Misses

Peabody Energy Q2 EPS $(0.23) Misses $(0.01) Estimate, Sales $890.100M Miss $944.200M Estimate

DSV (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSDVY#OTC">DSDVY</a>) reported quarterly earnings of $0.75 per share. This is a 21.87 percent decrease over earnings of $0.96 per share from the same period last year. The company reported $9.418 billion in sales this quarter. This is a 58.58 percent increase over sales of $5.939 billion the same period last year.

DSDVY

DSV Q2 EPS $0.75 Down From $0.96 YoY, Sales $9.418B Up From $5.939B YoY

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) with a Outperform and lowers the price target from $19 to $15.

ANIK

Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

WIIM

ABBV

AbbVie shares are trading higher after the company raised 2025 guidance.

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) raises FY2025 Adj EPS guidance from $11.67-$11.87 to $11.88-$12.08 vs $12.24 analyst estimate..

Guidance

AbbVie Raises FY2025 Adj EPS Guidance from $11.67-$11.87 to $11.88-$12.08 vs $12.24 Est

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported quarterly earnings of $2.97 per share which missed the analyst consensus estimate of $3.23 by 7.94 percent. This is a 12.08 percent increase over earnings of $2.65 per share from the same period last year. The company reported quarterly sales of $15.423 billion which beat the analyst consensus estimate of $14.977 billion by 2.98 percent. This is a 6.65 percent increase over sales of $14.462 billion the same period last year.

Earnings Beats

AbbVie Q2 Adj. EPS $2.97 Misses $3.23 Estimate, Sales $15.423B Beat $14.977B Estimate

DYAI

Dyadic Prices Public Offering Of 6.05M Common Shares; Closing Expected August 1, Proceeds To Fund Product Development And Operations

Banco Santander Chile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSAC#NYSE">BSAC</a>) reported quarterly earnings of $0.60 per share which missed the analyst consensus estimate of $0.62 by 3.23 percent. This is a 22.45 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $616.436 million which missed the analyst consensus estimate of $757.480 million by 18.62 percent. This is a 15.32 percent increase over sales of $534.546 million the same period last year.

BSAC

Banco Santander Chile Q2 EPS $0.60 Misses $0.62 Estimate, Sales $616.436M Miss $757.480M Estimate

Stephens &amp; Co. analyst Jim Salera maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Overweight and raises the price target from $400 to $425.

WING

Stephens & Co. Maintains Overweight on Wingstop, Raises Price Target to $425

Xerox Partners With Kyocera To Re-Enter Cut-Sheet Inkjet Market; Expands Production Portfolio With High-Speed Inkjet Presses

Barrington Research analyst Michael Petusky maintains Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) with a Outperform and maintains $38 price target.

OPCH

Barrington Research Maintains Outperform on Option Care Health, Maintains $38 Price Target

MPLX

MPLX LP To Acquire Northwind Midstream For $2.375B In Cash Consideration

Needham analyst Scott Berg maintains SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) with a Buy and lowers the price target from $210 to $160.

SPSC

Needham Maintains Buy on SPS Commerce, Lowers Price Target to $160

Rosenblatt analyst Catharine Trebnick maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Buy and maintains $235 price target.

Rosenblatt Maintains Buy on Palo Alto Networks, Maintains $235 Price Target

SNGX

Soligenix shares are trading higher after the company announced positive Phase 2a proof-of-concept results for SGX945 in Behçet's Disease, demonstrating biological efficacy.

CBIO

Crescent Biopharma Q2 EPS $(4.93) Misses $(1.11) Estimate, Cash Balance Of $152.6M

Press Releases

Zedge Increases Cost Reduction Efforts to a Targeted $4 Million Annually

Zedge To Report Second Fiscal Quarter 2025 Results

Zedge Announces Second Quarter Fiscal 2025 Results

Events

Zedge to Present at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub

Zedge To Report Third Fiscal Quarter 2025 Results

Zedge to Participate in the "2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow" Virtual Conference Presented by Maxim Group

Zedge Launches DataSeeds.AI, a Content Marketplace for AI Training Sets

Contracts

Zedge's DataSeeds.AI Releases Foundational Dataset for Computer Vision and Generative AI in Collaboration with Perle.ai and Émet Research

Zedge Announces Third Quarter Fiscal 2025 Results

Zedge's Emojipedia Celebrates World Emoji Day 2025 with Launch of Digital Stickers Vertical

Antelope Enterprise Holdings Limited - Class A Ordinary Shares

Antelope Ent Hldgs

The Arena Group Holdings, Inc. Common Stock

Arena Group Holdings

BuzzFeed

Cheer Holding, Inc. - Class A Ordinary Share

Cheer Holding

DHI Group

Fangdd Network Group Ltd. - Class A Ordinary Shares

Fangdd Network Group

Phoenix New Media Limited American Depositary Shares, each representing 48 Class A ordinary shares.

Comments

Zedge

Zedge (ZDGE) Opzioni

Zedge (AMEX:ZDGE) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO